Overview
Fibromyalgia is the third most common musculoskeletal condition in terms of prevalence, after lumbar pain and osteoarthritis. Its prevalence is around 2-4 % and is more frequent in women than in men; the prevalence is highest in age the range of 40-60 years.
Description
Group A (Control Group): Patients will receive exercises, and sham Non-Invasive Neuromodulation, 3 sessions per week (one hour for each session) for 4 weeks.
Group B (Study Group): Patients will receive exercises as in group (A) in addition to Non-Invasive Neuromodulation 3 sessions per week (one hour for each session) for 4 weeks.
Eligibility
Inclusion Criteria:
- Patients fibromyalgia from both genders.
- The duration of fibromyalgia is more than 6 month (all patients with history of cervical or lumbar pain) and following diagnosis of FM using the 2016 revised FM criteria, on the basis of the ACR-2010 criteria.
- Their ages will be ranged from 25-35 years old.
- They will be medically stable and have sufficient cognitive abilities that enable them to understand and follow instruction according to Montreal Cognitive Assessment (MoCA) >26.
Exclusion Criteria:
- Other Neurological diseases as stroke , multiple sclerosis, Parkinson's disease and motor neuron disease
- Pacemaker
- Spinal fusion-cervical or lumbar
- Metal implants in the spine
- Pregnancy
- Epilepsy
- Severe psychiatric disorder or alcohol and drug abuse.
- Unstable medical condition which could compromise the participant's welfare or confound the study results.
- Uncontrolled blood pressure or diabetes
- Visual or auditory problems.
- Active inflammatory conditions